Contract Manufacturing of Novel In-Licensed Drugs – 2020 PharmSource Edition
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
This expert trend report explores in-licensing trends among FDA New Molecule Entity (NME) approvals 2014-2018, and analyzes how licensing patterns affect propensity to outsource finished dose manufacture. This report is critical for establishing an understanding of the ways bio/pharmaceutical companies source their drugs, and the factor that make them more likely to engage a contract manufacturing organization (CMO).
Scope
This 24-page report gives important, expert insight you won’t find in any other source. 12 tables and figures throughout the report illustrate major points and trends This report is required reading for:
• CMO executives who must have a deep understanding of the NME approvals landscape to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Pharmaceutical and biotech companies evaluating potential licensing deals as a licensor or licensee.
• Investors that need a deeper understanding of the market to identify and value potential investment targets.
Reasons to Buy
Overview of novel drugs (NMEs) approved by FDA 2014-2018
Detailed analysis of dose outsourcing likelihood by: licensing status, market cap, molecule type
Spotlight on licensing deals and outsourcing propensity
Detailed methodology explains use of data from the GlobalData Pharma Intelligence Center databases
Astellas Pharma
AstraZeneca Plc
Bristol-Myers Squibb
Cabaret Biotech
ClearView Healthcare Partners
CSL
Cytovant Sciences
Eli Lilly and Co
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Legend Biotech
Les Laboratoires Servier
Medigene
Merck & Co Inc
Neurocrine Biosciences
Novartis
Pfizer Inc
Roche
Sanofi
Sarepta Therapeutics
Taiho Pharmaceutical Co
Takeda Pharmaceutical Co Ltd
Vericel
Voyager Therapeutics
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.